Table 2.

Analytes Significantly Changed Over the Treatment Period (Week 24)

Analyte	P	q
PARC	< .001	< 0.001
VEGF-D	< .001	< 0.001
SPD	< .001	< 0.001
TIE 2	< .001	< 0.001
TRAILR3	< .001	< 0.001
Eotaxin 2	< .001	< 0.001
MIP1 beta	< .001	< 0.001
P selectin	< .001	0.001
Resistin	< .001	0.004
EN-RAGE	< .001	0.005
Folate receptor gamma	< .001	0.007
GDF 15	< .001	0.007
Periostin	< .001	0.008
MMP9 total	< .001	0.009
SDF1	< .001	0.009
TATI	< .001	0.01
TFF3	.001	0.01
Thrombomodulin	.001	0.02
Vaspin	.001	0.02
NGAL	.002	0.02
CCL21	.002	0.03
CD5L	.003	0.03
VEGFR-3	.003	0.03
CCL15	.003	0.03
TARC	.004	0.03
EGF	.004	0.03
HGFR	.004	0.03
Haptoglobin	.006	0.048
CEA	.006	0.048
PECAM 1	.007	0.048
ENA 78	.007	0.048
SHBG	.007	0.048

CCL = CC motif chemokine; CD5L = CD5 antigen like; CEA = carcinoembryonic antigen; EGF = epidermal growth factor; ENA 78 = epithelial-derived neutrophil activating protein 78; HGFR = hepatocyte growth factor receptor; MIP1 beta = macrophage inflammatory protein 1 beta; PECAM1 = platelet endothelial cell adhesion molecule; SDF1 = stromal cell–derived factor 1; SHBG = sex hormone–binding globulin; SPD = pulmonary surfactant associated protein D; TARC = thymus and activation regulated chemokine; TATI = pancreatic secretory trypsin inhibitor; TFF3 = Trefoil factor 3; TIE 2 = tyrosine kinase with Ig and EGF homology domains 2; Vaspin = visceral adipose tissue derived serpin A12; VEGF-D = vascular endothelial growth factor D; VEGFR-3 = vascular endothelial growth factor receptor-3.